Evaluation of interleukin 8 polymorphisms (-251T/A and +781C/T) in patients with hepatocellular carcinoma: a meta-analysis

Basit Öğe Kaydı
dc.authoridSadeghi, Masoud/0000-0002-3586-3012
dc.contributor.authorAleagha, Omid Emami
dc.contributor.authorMoeinzadeh, Forouzan
dc.contributor.authorShokouh, Seyedeh Farnaz Moeini
dc.contributor.authorDogan, Erkan
dc.contributor.authorSadeghi, Masoud
dc.date.accessioned2024-09-29T16:09:38Z
dc.date.available2024-09-29T16:09:38Z
dc.date.issued2021
dc.departmentKarabük Üniversitesien_US
dc.description.abstractAim of the study: We reported the association between interleukin 8 (IL-8) polymorphisms (-251T/A and +781C/T) and hepatocellular carcinoma (HCC) risk in a meta-analysis. Material and methods: Scopus, PubMed, Web of Science, and Cochrane Library databases were searched until 21 November 2021. The analyses were performed by RevMan 5.3 software using odds ratios (ORs) and 95% confidence intervals (Cis). Also, the analysis of publication bias was performed by CMA 2.0 software. Results: Searching databases/sources, five articles including ten studies were entered into the meta-analysis. The pooled ORs for -251T/A polymorphism were 1.07 (p = 0.55), 1.04 (p = 0.75), 1.31 (p = 0.24), 1.24 (p = 0.31), and 1.85 (p = 0.29) for allele, homozygote, heterozygote, recessive and dominant models, respectively. With regards to +781C/Tpolymorphism, the pooled ORs were 0.74 (p = 0.07), 0.53 (p = 0.03), 0.83 (p = 0.41), 0.75 (p = 0.19), and 0.57 (p = 0.02) for allele, homozygote, heterozygote, recessive, and dominant models, respectively. Conclusions: The findings of the meta-analysis showed a lack of significant association between IL-8 (-251T/A) polymorphism and the HCC risk, whereas the TT genotype of IL-8 (+781C/T) polymorphism had a protective role in HCC.en_US
dc.description.sponsorshipResearch Council of Kermanshah University of Medical Sciencesen_US
dc.description.sponsorshipThe authors gratefully acknowledge the Research Council of Kermanshah University of Medical Sciences for the financial support.en_US
dc.identifier.doi10.5114/ceh.2021.109424
dc.identifier.endpage285en_US
dc.identifier.issn2392-1099
dc.identifier.issn2449-8238
dc.identifier.issue3en_US
dc.identifier.pmid34712829en_US
dc.identifier.scopus2-s2.0-85116993369en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage278en_US
dc.identifier.urihttps://doi.org/10.5114/ceh.2021.109424
dc.identifier.urihttps://hdl.handle.net/20.500.14619/7686
dc.identifier.volume7en_US
dc.identifier.wosWOS:000724731900005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTermedia Publishing House Ltden_US
dc.relation.ispartofClinical and Experimental Hepatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjecthepatocellular carcinomaen_US
dc.subjectinterleukin 8en_US
dc.subjectliver canceren_US
dc.subjectpolymorphismen_US
dc.titleEvaluation of interleukin 8 polymorphisms (-251T/A and +781C/T) in patients with hepatocellular carcinoma: a meta-analysisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu